CY1121869T1 - Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας - Google Patents
Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτηταςInfo
- Publication number
- CY1121869T1 CY1121869T1 CY20191100840T CY191100840T CY1121869T1 CY 1121869 T1 CY1121869 T1 CY 1121869T1 CY 20191100840 T CY20191100840 T CY 20191100840T CY 191100840 T CY191100840 T CY 191100840T CY 1121869 T1 CY1121869 T1 CY 1121869T1
- Authority
- CY
- Cyprus
- Prior art keywords
- genetically modified
- human
- mice
- major histocompatibility
- histocompatibility complex
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 1
- 241000699670 Mus sp. Species 0.000 title 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
- 210000002257 embryonic structure Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η εφεύρεση παρέχει γενετικά τροποποιημένα μη ανθρώπινα ζώα, τα οποία εκφράζουν χιμαιρικό, ανθρώπινο/μη ανθρώπινο MHC I πολυπεπτίδιο ή/και ανθρώπινο ή ανθρωποποιημένο πολυπεπτίδιο β2 μικροσφαιρίνης, καθώς και μη ανθρώπινα έμβρυα, κύτταρα και ιστούς, φέροντα το ίδια. Παρέχονται επίσης δομές για τη δημιουργία των προαναφερθέντων γενετικά τροποποιημένων ζώων και μέθοδοι για τη δημιουργία τους. Παρέχονται μέθοδοι χρήσης των γενετικά τροποποιημένων ζώων για τη μελέτη διαφόρων παραμέτρων του ανθρώπινου ανοσοποιητικού συστήματος.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552587P | 2011-10-28 | 2011-10-28 | |
US201161552582P | 2011-10-28 | 2011-10-28 | |
US201261700908P | 2012-09-14 | 2012-09-14 | |
EP12787255.4A EP2770821B1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
PCT/US2012/062042 WO2013063346A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121869T1 true CY1121869T1 (el) | 2020-10-14 |
Family
ID=47178940
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101223T CY1119657T1 (el) | 2011-10-28 | 2017-11-22 | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας |
CY20191100840T CY1121869T1 (el) | 2011-10-28 | 2019-08-07 | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101223T CY1119657T1 (el) | 2011-10-28 | 2017-11-22 | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας |
Country Status (25)
Country | Link |
---|---|
US (3) | US9615550B2 (el) |
EP (4) | EP2770821B1 (el) |
JP (4) | JP6154391B2 (el) |
KR (3) | KR102074145B1 (el) |
CN (3) | CN104039132B9 (el) |
AU (3) | AU2012324016C1 (el) |
BR (1) | BR112014009259A2 (el) |
CA (2) | CA2850387A1 (el) |
CY (2) | CY1119657T1 (el) |
DK (2) | DK3262932T3 (el) |
ES (3) | ES2962287T3 (el) |
HK (2) | HK1200272A1 (el) |
HR (2) | HRP20171761T1 (el) |
HU (2) | HUE035652T2 (el) |
IL (3) | IL232097A (el) |
LT (2) | LT3262932T (el) |
MX (2) | MX355725B (el) |
MY (2) | MY164836A (el) |
NZ (1) | NZ734532A (el) |
PL (2) | PL2770821T3 (el) |
PT (2) | PT2770821T (el) |
RS (2) | RS56656B1 (el) |
SG (2) | SG11201400933VA (el) |
SI (2) | SI2770821T1 (el) |
WO (1) | WO2013063346A1 (el) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
HUE045478T2 (hu) * | 2013-02-20 | 2019-12-30 | Regeneron Pharma | Humanizált T-sejt koreceptorokat expresszáló egerek |
JP6444321B2 (ja) * | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
JP6456351B2 (ja) * | 2013-03-11 | 2019-01-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | キメラ主要組織適合複合体(mhc)クラスi分子を発現する遺伝子導入マウス |
US9193977B2 (en) | 2013-09-23 | 2015-11-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized signal-regulatory protein gene |
RS58465B1 (sr) | 2013-10-15 | 2019-04-30 | Regeneron Pharma | Humanizovane il-15 životinje |
US10278373B2 (en) | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
KR102439412B1 (ko) | 2014-04-08 | 2022-09-02 | 리제너론 파아마슈티컬스, 인크. | 인간화된 Fc-감마 수용체를 갖는 비-인간 동물 |
EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
NO2785538T3 (el) | 2014-05-07 | 2018-08-04 | ||
RS60097B1 (sr) | 2014-06-19 | 2020-05-29 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1 |
CA2959428A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
LT3223605T (lt) | 2014-11-24 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, ekspresuojantys humanizuotą cd3 kompleksą |
KR102617691B1 (ko) | 2014-12-05 | 2023-12-27 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 분화 클러스터 47 유전자를 가진 비인간 동물 |
LT3808775T (lt) * | 2014-12-09 | 2024-07-10 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
CN107249318A (zh) | 2014-12-10 | 2017-10-13 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
FI3280257T3 (fi) | 2015-04-06 | 2023-09-07 | Regeneron Pharma | Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä |
SG11201708380WA (en) * | 2015-04-13 | 2017-11-29 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
SI3376857T1 (sl) | 2015-11-20 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Nehumane živali, ki imajo humaniziran gen 3 za aktivacijo limfocitov |
KR102493894B1 (ko) | 2016-02-29 | 2023-01-31 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 tmprss 유전자를 갖는 설치류 |
PT3462853T (pt) | 2016-06-03 | 2023-04-21 | Regeneron Pharma | Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena |
CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
JP7139419B2 (ja) | 2017-09-29 | 2022-09-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ttr遺伝子座を含む非ヒト動物および使用方法 |
CN111386039B (zh) * | 2017-09-29 | 2023-02-28 | 瑞泽恩制药公司 | 经基因修饰的啮齿动物基因组 |
EP4299732A3 (en) | 2017-11-30 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Rats comprising a humanized trkb locus |
CN112040769B (zh) * | 2018-03-24 | 2023-05-16 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途 |
SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
JP2021530970A (ja) | 2018-07-16 | 2021-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Ditraの非ヒト動物モデルおよびその使用 |
ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
AU2020286382A1 (en) | 2019-06-04 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use |
TW202112229A (zh) | 2019-06-07 | 2021-04-01 | 美商雷傑納榮製藥公司 | 包含人化白蛋白基因座之非人的動物 |
WO2021139799A1 (en) * | 2020-01-10 | 2021-07-15 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric mhc protein complex |
WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
JP2024500399A (ja) | 2020-12-16 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化Fcアルファ受容体を発現するマウス |
MX2023010796A (es) | 2021-03-31 | 2023-09-27 | Regeneron Pharma | Ratones modificados geneticamente que comprenden componentes del sistema inmunitario celular humanizados con diversidad mejorada del repertorio del receptor de celulas t beta (tcrb). |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
AU633958B2 (en) | 1989-07-25 | 1993-02-11 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
DK1017721T3 (da) | 1997-09-16 | 2009-04-20 | Univ Oregon Health & Science | Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler |
US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
WO2001027291A1 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
WO2005085438A1 (ja) | 2004-03-09 | 2005-09-15 | Nagoya Industrial Science Research Institute | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
MX2009011500A (es) * | 2007-04-23 | 2010-01-29 | Schering Corp | Anticuerpos anti-mdl-1. |
TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之es-細胞衍生的老鼠 |
US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
HUE045478T2 (hu) | 2013-02-20 | 2019-12-30 | Regeneron Pharma | Humanizált T-sejt koreceptorokat expresszáló egerek |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
JP6444321B2 (ja) | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
EP3004361A1 (en) * | 2013-06-03 | 2016-04-13 | Theravectys | Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence |
US10278373B2 (en) * | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
FI3280257T3 (fi) | 2015-04-06 | 2023-09-07 | Regeneron Pharma | Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä |
-
2012
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en active Application Filing
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active IP Right Grant
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active IP Right Grant
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 CN CN202110831383.7A patent/CN113564188A/zh active Pending
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 CA CA3074400A patent/CA3074400A1/en active Pending
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active IP Right Grant
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 MX MX2020010763A patent/MX2020010763A/es unknown
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
-
2015
- 2015-01-29 HK HK15101011.6A patent/HK1200272A1/xx unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-15 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/zh unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121869T1 (el) | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
CY1122700T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (μηc) ii | |
CY1123831T1 (el) | Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων | |
CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
CY1121979T1 (el) | Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις | |
CY1123714T1 (el) | Μη-ανθρωπινα ζωα που εκφραζουν ανθρωποποιημενο cd3 συμπλοκο | |
CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
CY1125057T1 (el) | Anti-cd277 αντισωματα και χρησεις αυτων | |
CY1120845T1 (el) | Στοχευομενη τροποποιηση γονιδιωματος αρουραιου | |
CY1121410T1 (el) | Μη-ανθρωπινα ζωα που εχουν ενα εξανθρωποποιημενο γονιδιο ρυθμιστικης πρωτεϊνης σηματος | |
CY1122179T1 (el) | Μεθοδοι και συνθεσεις για την παραγωγη ή την διατηρηση πολυδυναμων κυτταρων | |
CY1121405T1 (el) | Εξανθρωποποιημενα il-15 ζωα | |
CY1125029T1 (el) | Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων | |
CO2019013609A2 (es) | Vectores de neoantígeno de alfavirus | |
CO2017000510A2 (es) | Constructos de car | |
BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
CY1119071T1 (el) | Εξανθρωποποιημενα il-7 τρωκτικα | |
BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
UY35468A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 | |
CY1123046T1 (el) | Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ | |
BR112012027917A2 (pt) | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano | |
ECSP14005975A (es) | Anticuerpos anti-PHF-tau y sus usos | |
MX2023009421A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. |